The deal, structured as an all-stock transaction, gives Tempus control of Personalis' NeXT Personal cancer detection test ...

Tempus AI Inc., which uses artificial intelligence for tailored disease prevention and treatment, has agreed to buy Personalis Inc. in a deal that gives the cancer-testing company an equity valuation ...

Tempus AI, a healthcare tech company, is a favorite of investor Cathie Wood. Personalis does cancer testing.

Tempus AI has agreed to buy the rest of genomics company Personalis in a deal that expands the technology company's capabilities in minimal residual disease. Tempus, which already owns more than 12% ...

By Christy Santhosh July 20 (Reuters) - Tempus AI said on Monday it would buy Personalis in a deal valued at about $1.5 billion, adding a cancer test to the AI-enabled precision medicine firm's ...

Tempus AI, a company that brings artificial intelligence to diagnostics, is growing its capabilities in oncology through a $1.5 billion deal to buy Personalis and its commercialized test for detecting ...

Tempus AI acquires Personalis to expand its oncology testing portfolio and address a $20B+ MRD detection market with 10% penetration. Personalis brings innovative cancer detection technology, robust ...

Tempus AI, a technology platform leveraging AI to advance precision medicine and patient care, recently announced its plans to acquire Personalis, a company specializing in early detection of small ...

Tempus AI has agreed to acquire the cancer genomics company Personalis in a deal valued at about $1.5 billion, the companies announced July 20. The acquisition builds on a partnership the two ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Personalis shareholders will ...